Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Sandoz Group Ltd ( (CH:SDZ) ).
Sandoz has filed an antitrust lawsuit against Amgen in the US, accusing it of unlawfully maintaining its market dominance with the drug Enbrel by blocking competition from biosimilars like Sandoz’s Erelzi. This legal action aims to clear the path for Erelzi’s launch, potentially benefiting millions of Americans with inflammatory diseases by providing a more affordable treatment option and challenging Amgen’s market position.
More about Sandoz Group Ltd
Sandoz is a global leader in generic and biosimilar medicines, headquartered in Basel, Switzerland. With a history dating back to 1886, the company offers a diverse portfolio of approximately 1,300 products addressing various diseases. Sandoz employs over 20,000 people worldwide and recorded net sales of USD 10.4 billion in 2024.
YTD Price Performance: -5.19%
Average Trading Volume: 3,609
Technical Sentiment Signal: Strong Buy
Current Market Cap: $17.1B
See more insights into SDZ stock on TipRanks’ Stock Analysis page.